Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4

NCT01884402 · clinicaltrials.gov ↗

COMPLETED

Status

770

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Peginterferon alfa-2a
DRUG: Ribavirin

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla